An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
Summary: In adults with type 2 diabetes (T2D), mycoprotein and guar gum significantly reduced postprandial glucose (PG) compared to a…
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
A phase 1 mechanistic study in adults with obesity found tirzepatide did not alter metabolic adaptation but increased fat oxidation and reduced calorie intake versus placebo. PICO summary and expert commentary.
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide’s cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Once-weekly semaglutide 2.4 mg cut body weight by an estimated 8.3% more than placebo over 44 weeks in Chinese adults with overweight or obesity in the STEP 7 trial. PICO summary and expert commentary.